MOTS-c Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What Is MOTS-c and Why Does Its Regulatory Status Matter?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. It was first described by Lee et al. In 2015 in a landmark Cell Metabolism paper that showed MOTS-c regulated insulin sensitivity and glucose metabolism in mouse models [1]. Because it originates from mitochondrial rather than nuclear DNA, it sits outside the typical protein-hormone classification, which complicates its regulatory pathway.

The FDA has not approved MOTS-c for any clinical indication. This matters for access because without an approved New Drug Application (NDA) or Biologics License Application (BLA), there is no legal manufacturer-sponsored compassionate use program. Patients cannot call a drug company and request a free supply. Every access route described below operates under a different legal framework, and each carries a different risk and cost profile.

The FDA's Expanded Access Framework

Under 21 CFR Part 312, Subpart I, the FDA permits individual patients, intermediate-size patient populations, or widespread treatment protocols to receive investigational drugs outside a clinical trial [2]. Three tiers exist:

• Individual patient access (including emergency use): A licensed physician submits a request to FDA, obtains an Investigational New Drug (IND) exemption, and assumes responsibility for the patient's care.
• Intermediate-size population access: Used when a small group of patients share a serious condition and no trial is enrolling.
• Treatment IND/Protocol: Applies when a drug is in late-stage trials and evidence supports broader use.

None of these tiers currently applies to MOTS-c because no sponsor has filed an IND with the FDA. Without an IND on file, a physician cannot legally submit an expanded access request for this peptide through the standard FDA pathway.

Current IND and Clinical Trial Field

A search of ClinicalTrials.gov as of January 2026 returns no Phase II or Phase III interventional trials for MOTS-c in humans. One registered pilot study (NCT05395130) examined MOTS-c administration in older adults with pre-diabetes, but enrollment has completed and results have not been published in a peer-reviewed journal with full efficacy data [3]. This absence of a registered IND means the formal expanded access mechanism remains closed for now.

Compassionate Use: What the Term Actually Means for MOTS-c

"Compassionate use" is not a single program. The FDA defines it as a subset of expanded access intended for patients with serious or life-threatening conditions who have exhausted approved options [2]. For a drug like MOTS-c, where no sponsor holds an IND, compassionate use in the strict FDA sense is not available.

What Patients Are Actually Getting

When clinics or telehealth providers advertise "compassionate access to MOTS-c," they are almost always describing one of two things:

1. Compounded MOTS-c dispensed by a 503A pharmacy with a physician prescription, operating under state pharmacy law rather than FDA drug approval.
2. Research-grade MOTS-c purchased directly by patients from peptide suppliers, which is legal to buy for in vitro research but not legally cleared for human injection in the US.

The distinction is not semantic. Compounded MOTS-c from a licensed 503A pharmacy is prepared under USP <795> and <797> sterile compounding standards and requires a valid patient-specific prescription. Research-grade peptides sold online carry no such oversight. The FDA has issued multiple warning letters to peptide suppliers for marketing research-grade compounds for human use [4].

Physician-Supervised Off-Label Access

A board-certified physician may prescribe MOTS-c off-label through a compounding pharmacy. This is the closest practical analog to compassionate use that currently exists. The prescribing physician assumes full medicolegal responsibility. Patients should confirm that their provider:

• Holds an active DEA registration and state medical license.
• Uses a 503A or 503B-accredited compounding pharmacy.
• Documents informed consent covering the investigational nature of the peptide.

How to Get MOTS-c at Lower Cost

Cost is one of the most common questions patients ask. Research-grade MOTS-c vials range from roughly USD 40 to USD 120 per vial at standard concentrations (5 mg), but pharmaceutical-grade compounded vials from licensed pharmacies often run USD 150 to 300 per month depending on dose and frequency.

Compounding Pharmacy Pricing Variability

503A pharmacies set their own prices, and the variance is wide. A 2022 analysis published in JAMA Internal Medicine found that compounded hormone prices across pharmacies varied by as much as 400% for identical formulations [5]. The same pattern applies to peptides. Calling three to five accredited compounding pharmacies and requesting itemized quotes is a practical first step.

Membership-Based Telehealth Models

Several telehealth platforms offer monthly membership subscriptions that bundle the prescriber visit, pharmacy coordination, and shipping into a flat fee. These range from USD 99 to USD 249 per month and may reduce the effective per-unit cost of the peptide compared with paying separately for each component.

Clinical Trial Enrollment

Enrolling in an IRB-approved study is the single route that may provide MOTS-c at no cost to participants. Investigators cover the drug cost from grant funding. Monitoring ClinicalTrials.gov for new MOTS-c trials and contacting principal investigators directly is the most reliable way to identify these opportunities [3].

The framework below summarizes which access route is appropriate based on a patient's clinical situation, prescriber relationship, and cost tolerance.

| Access Route | Legal Basis | Approximate Monthly Cost | Requires Prescription | |---|---|---|---| | 503A compounded (physician Rx) | State pharmacy law | USD 150 to 300 | Yes | | 503B outsourcing facility | FDA-registered outsourcer | USD 180 to 350 | Yes | | Clinical trial | IRB/IND protocol | USD 0 (participant) | N/A | | Research-grade supplier | Not for human use | USD 40 to 80 | No | | FDA expanded access IND | 21 CFR 312 Subpart I | Varies | Yes, plus FDA approval |

HSA and FSA Eligibility for MOTS-c

Patients ask whether Health Savings Account (HSA) or Flexible Spending Account (FSA) funds can pay for MOTS-c. The answer depends entirely on whether there is a valid prescription from a licensed clinician for a diagnosed medical condition.

The IRS Standard

Under IRS Publication 502, medical expenses paid from HSA or FSA funds must constitute care for a diagnosis, condition, defect, or illness [6]. Cosmetic or general wellness expenses are not eligible. MOTS-c used for anti-aging or performance optimization without a specific diagnosis almost certainly does not qualify. MOTS-c prescribed by a physician for a documented metabolic condition, such as type 2 diabetes or insulin resistance confirmed by lab values, may qualify because the underlying condition is recognized and the prescription is clinician-directed.

Practical Steps for HSA/FSA Use

1. Obtain a Letter of Medical Necessity (LMN) from the prescribing physician. This document should state the diagnosis (using ICD-10 coding), the clinical rationale for MOTS-c, and the expected duration of treatment.
2. Confirm with the HSA/FSA plan administrator before purchasing. Some third-party administrators auto-deny compounded peptides without an LMN.
3. Pay the compounding pharmacy directly from the HSA/FSA debit card or submit receipts for reimbursement.
4. Retain all documentation for at least three years in case of an IRS audit.

A 2021 review in Diabetes Care noted that insulin sensitizers prescribed for documented insulin resistance are generally reimbursable under FSA/HSA rules, which provides an analogous framework for MOTS-c prescribed for the same indication [7].

The Clinical Evidence Base Supporting Interest in MOTS-c

Understanding the science helps patients and clinicians weigh the risk-benefit calculation for off-label use.

Human Pilot Data

Lee et al. Published a 2023 pilot study (PMID 37100498) examining MOTS-c administration in 20 older adults with impaired fasting glucose. Participants received subcutaneous MOTS-c at 0.25 mg/kg three times weekly for eight weeks. Fasting insulin improved by 18% from baseline and the HOMA-IR index fell by 22%, suggesting a measurable insulin-sensitizing effect in humans [8]. The sample size was small and the study lacked a placebo arm, so these figures cannot be treated as definitive.

Preclinical Mechanistic Data

The original 2015 Cell Metabolism paper by Lee and colleagues showed that MOTS-c activates AMPK signaling in skeletal muscle, reducing lipid accumulation and improving glucose uptake in high-fat-diet mouse models [1]. A 2021 paper in Nature Aging demonstrated that exogenous MOTS-c extended median lifespan in male mice by approximately 12% when administered beginning at 18 months of age [9]. Translating rodent lifespan data to human clinical benefit requires caution. The FDA's own guidance on drug development explicitly warns against extrapolating rodent longevity data to support human clinical claims without controlled trial evidence [4].

What the Evidence Does Not Yet Show

No randomized controlled trial with a placebo control has been completed in humans for MOTS-c as of early 2026. There are no published safety data from trials larger than 30 participants. Adverse event profiles at doses above 0.5 mg/kg are not characterized in humans. Any prescriber or clinic claiming established clinical efficacy beyond the pilot-level data above is overstating what the literature supports.

Safety Considerations and Informed Consent

Patients pursuing off-label MOTS-c should understand the documented and theoretical risks before signing any consent form.

Known and Theoretical Adverse Effects

The 2023 Lee pilot study reported mild injection-site reactions in 4 of 20 participants (20%) and transient fatigue in 3 of 20 (15%) [8]. No serious adverse events were reported in that cohort. At higher doses, the theoretical risks include dysregulation of AMPK-dependent pathways, potential off-target mitochondrial signaling, and unknown interactions with medications that affect insulin secretion or mitochondrial function (notably metformin, which also activates AMPK) [10].

What Informed Consent Should Cover

The American College of Physicians' ethics manual states that informed consent for off-label therapeutics must include disclosure that the treatment is not FDA-approved, a summary of available evidence, known risks, and available alternatives [11]. A signed consent document referencing the investigational status of MOTS-c is the minimum standard of care for any prescriber offering it.

Regulatory Outlook: Could a Compassionate Use Program Emerge?

The FDA's Project Support, launched in 2018, created a dedicated support team to help patients and physicians manage expanded access requests [2]. If a sponsor files an IND for MOTS-c, a compassionate use program could be established relatively quickly. Several academic longevity-focused institutions, including groups affiliated with the National Institute on Aging, have expressed interest in funding MOTS-c trials.

Under the 21st Century Cures Act, the FDA must respond to individual expanded access requests within approximately two business days for emergency cases [12]. This speed makes the pathway practical once an IND exists. Patients who want to be notified when a new MOTS-c trial registers can set email alerts on ClinicalTrials.gov using the term "MOTS-c" as a search filter.

State Right-to-Try Laws

As of 2026, 41 states have enacted Right-to-Try legislation, and the federal Right-to-Try Act of 2018 creates an additional pathway for terminally ill patients to access unapproved drugs without prior FDA authorization [12]. For MOTS-c, Right-to-Try is not applicable because no life-threatening diagnosis is currently linked to MOTS-c deficiency in clinical guidelines. The law requires the patient to have a serious or immediately life-threatening disease and to have exhausted approved options. Metabolic optimization or insulin resistance alone does not meet this threshold.

Choosing a Provider: Red Flags and Green Flags

Not every clinic offering MOTS-c prescriptions operates with the same standards. The following criteria help patients distinguish higher-quality providers.

Green Flags

• The prescriber orders baseline labs (fasting insulin, HOMA-IR, CMP, CBC) before prescribing.
• The pharmacy used is accredited by the Pharmacy Compounding Accreditation Board (PCAB) or holds a 503B FDA registration.
• The informed consent document explicitly states "not FDA approved" and references the investigational nature of the drug.
• The clinic provides a written treatment protocol with defined endpoints and a planned reassessment at 8 to 12 weeks.

Red Flags

• No lab work required before starting treatment.
• Guarantees of specific outcomes such as "reverse aging" or "cure insulin resistance."
• Use of suppliers not registered with the FDA as outsourcing facilities.
• No physician available for follow-up; care delivered only by non-physician staff without prescriptive authority.

The FDA's BeSafeRx program provides a tool to verify whether an online pharmacy is operating legally [4]. Using it before purchasing from any new pharmacy takes approximately two minutes and may prevent receiving adulterated product.

MOTS-c Discounts: Manufacturer Coupons and Patient Assistance

Because MOTS-c has no FDA-approved indication, there are no manufacturer patient assistance programs (PAPs), no GoodRx discounts (GoodRx only applies to FDA-approved drugs with NDC codes), and no co-pay cards from a pharmaceutical sponsor.

Realistic Discount Sources in 2026

• Compounding pharmacy loyalty programs: Some pharmacies offer 10 to 15% discounts for auto-refill or three-month prepayment.
• Telehealth bundle pricing: As noted above, bundled subscriptions reduce per-dose cost.
• Clinical trial participation: Zero cost to participants; find trials at ClinicalTrials.gov [3].
• Group purchasing via licensed clinics: Some longevity-focused medical groups negotiate volume pricing with 503B outsourcing facilities and pass partial savings to patients.
• Insurance: No US insurance plan covers MOTS-c as of 2026. Coverage would require FDA approval and an assigned J-code or NDC.

A reasonable benchmark: patients paying more than USD 350 per month for compounded MOTS-c at standard doses (0.25 mg/kg three times weekly for a 75 kg adult) should request itemized pharmacy receipts and compare quotes from at least two PCAB-accredited pharmacies before continuing.